Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Oct 28

PMID 37894443

Authors

Thais Baccili Cury Megid

Abdul Rehman Farooq

Xin Wang

Elena Elimova

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is a global health concern, ranking fifth in cancer diagnoses and fourth in cancer-related deaths worldwide. Despite recent advancements in diagnosis, most cases are detected at advanced stages, resulting in poor outcomes. However, recent breakthroughs in genome analysis have identified biomarkers that hold positive clinical significance for GC treatment. These biomarkers and classifications offer the potential for more precise diagnostic and therapeutic approaches for GC patients. In this review, we explore the classification and molecular pathways in this disease, highlighting potential biomarkers that have emerged in recent studies including targeted therapies and immunotherapies. These advancements provide a promising direction for improving the management of GC.

Citing Articles

Helicobacter pylori and gastric cancer: mechanisms and new perspectives.

Duan Y, Xu Y, Dou Y, Xu D J Hematol Oncol. 2025; 18(1):10.

PMID: 39849657 PMC: 11756206. DOI: 10.1186/s13045-024-01654-2.

PCAT19: the role in cancer pathogenesis and beyond.

Hu H, Luo H, Deng Z Front Cell Dev Biol. 2025; 12:1435717.

PMID: 39744012 PMC: 11688190. DOI: 10.3389/fcell.2024.1435717.

SBL-JP-0004: A promising dual inhibitor of JAK2 and PI3KCD against gastric cancer.

Otifi H Oncol Res. 2024; 33(1):235-243.

PMID: 39735669 PMC: 11671411. DOI: 10.32604/or.2024.055677.

Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma.

Diaz Del Arco C, Estrada Munoz L, Ceron Nieto M, Molina Roldan E, Fernandez Acenero M, Garcia Gomez de Las Heras S Biomedicines. 2024; 12(7).

PMID: 39062081 PMC: 11275144. DOI: 10.3390/biomedicines12071508.

In silico analysis unveiling potential biomarkers in gallbladder carcinogenesis.

Gupta R, Bhushan R, Kumar S, Prasad S Sci Rep. 2024; 14(1):14570.

PMID: 38914609 PMC: 11196699. DOI: 10.1038/s41598-024-61762-4.

References

Pandey A, Tripathi S, Shukla S, Mahata S, Vishnoi K, Misra S . Differentially localized survivin and STAT3 as markers of gastric cancer progression: Association with Helicobacter pylori. Cancer Rep (Hoboken). 2020; 1(1):e1004. PMC: 7941477. DOI: 10.1002/cnr2.1004. View

Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E . Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68(22):9280-90. DOI: 10.1158/0008-5472.CAN-08-1776. View

Adewumi Akanji M, Rotimi D, Adeyemi O . Hypoxia-Inducible Factors as an Alternative Source of Treatment Strategy for Cancer. Oxid Med Cell Longev. 2019; 2019:8547846. PMC: 6710762. DOI: 10.1155/2019/8547846. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

Thuss-Patience P, Shah M, Ohtsu A, Van Cutsem E, Ajani J, Castro H . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5):640-653. DOI: 10.1016/S1470-2045(17)30111-0. View

Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y . FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene. 2018; 38(1):33-46. PMC: 6318220. DOI: 10.1038/s41388-018-0430-x. View

Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

10.

Sokolova O, Naumann M . NF-κB Signaling in Gastric Cancer. Toxins (Basel). 2017; 9(4). PMC: 5408193. DOI: 10.3390/toxins9040119. View

11.

Wang D, Gu Y, Yan X, Huo C, Wang G, Zhao Y . Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy. Front Oncol. 2022; 12:844260. PMC: 9005749. DOI: 10.3389/fonc.2022.844260. View

12.

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W . Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023; 14(1):8. PMC: 9810618. DOI: 10.1038/s41467-022-35431-x. View

13.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

14.

Bang Y, Van Cutsem E, Fuchs C, Ohtsu A, Tabernero J, Ilson D . KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019; 15(9):943-952. DOI: 10.2217/fon-2018-0581. View

15.

Xi Y, Zhang X, Luo Q, Gan H, Liu Y, Shao S . regulates stomach diseases by activating cell pathways and DNA methylation of host cells. Front Cell Dev Biol. 2023; 11:1187638. PMC: 10192871. DOI: 10.3389/fcell.2023.1187638. View

16.

Weston C, Davis R . The JNK signal transduction pathway. Curr Opin Cell Biol. 2007; 19(2):142-9. DOI: 10.1016/j.ceb.2007.02.001. View

17.

Ren Y, Guo T, Xu J, Liu Y, Huang J . The novel target of esophageal squamous cell carcinoma: lncRNA GASL1 regulates cell migration, invasion and cell cycle stagnation by inactivating the Wnt3a/β-catenin signaling. Pathol Res Pract. 2020; 217:153289. DOI: 10.1016/j.prp.2020.153289. View

18.

Young K, Smyth E, Chau I . Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Therap Adv Gastroenterol. 2015; 8(6):373-83. PMC: 4622287. DOI: 10.1177/1756283X15592586. View

19.

Fu J, Su X, Li Z, Deng L, Liu X, Feng X . HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021; 40(28):4625-4651. DOI: 10.1038/s41388-021-01863-w. View

20.

El Darsa H, El Sayed R, Abdel-Rahman O . Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?. J Exp Pharmacol. 2020; 12:349-361. PMC: 7547764. DOI: 10.2147/JEP.S242958. View